EGFR-MUTATED NSCLC
Clinical trials for EGFR-MUTATED NSCLC explained in plain language.
Never miss a new study
Get alerted when new EGFR-MUTATED NSCLC trials appear
Sign up with your email to follow new studies for EGFR-MUTATED NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat lung cancer: drug duo enters human testing
Disease control Recruiting nowThis early-phase study tests a new drug (ORIC-114) combined with an existing targeted therapy (amivantamab) in people with advanced lung cancer that has a specific genetic change (EGFR exon20 insertion). The goal is to find the best dose and see if the combination is safe and can…
Matched conditions: EGFR-MUTATED NSCLC
Phase: PHASE1 • Sponsor: ORIC Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 09:34 UTC
-
Scientists investigate why lung cancer comes back after targeted therapy
Knowledge-focused Recruiting nowThis study is for people with a specific type of lung cancer (EGFR-mutated NSCLC) who have had surgery and then took the drug osimertinib to prevent the cancer from coming back. Even with this treatment, the cancer sometimes returns. The study aims to understand why by looking at…
Matched conditions: EGFR-MUTATED NSCLC
Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica • Aim: Knowledge-focused
Last updated May 26, 2026 08:19 UTC